Search for other papers by Thozhukat Sathyapalan in
Google Scholar
PubMed
Search for other papers by Anne-Marie Coady in
Google Scholar
PubMed
Search for other papers by Eric S Kilpatrick in
Google Scholar
PubMed
Search for other papers by Stephen L Atkin in
Google Scholar
PubMed
Background Statin (HMG-CoA reductase) treatment is effective in the primary and secondary prevention of cardiovascular disease (CVD) events ( 1 , 2 ) and is generally safe and well tolerated ( 2 ). In the West of Scotland Coronary Study
Search for other papers by Melody Lok-Yi Chan in
Google Scholar
PubMed
Search for other papers by Sammy Wing-Ming Shiu in
Google Scholar
PubMed
Search for other papers by Ching-Lung Cheung in
Google Scholar
PubMed
Search for other papers by Anskar Yu-Hung Leung in
Google Scholar
PubMed
Search for other papers by Kathryn Choon-Beng Tan in
Google Scholar
PubMed
increases the expression of genes that promote cholesterol efflux ( 9 ). In addition to regulation by LXR, it has recently been suggested that statins may potentially influence IDOL expression in vitro ( 10 ). Statins are most widely used in lipid
Search for other papers by Lang Qin in
Google Scholar
PubMed
Search for other papers by Xiaoming Zhu in
Google Scholar
PubMed
Search for other papers by Xiaoxia Liu in
Google Scholar
PubMed
Search for other papers by Meifang Zeng in
Google Scholar
PubMed
Search for other papers by Ran Tao in
Google Scholar
PubMed
Search for other papers by Yan Zhuang in
Google Scholar
PubMed
Search for other papers by Yiting Zhou in
Google Scholar
PubMed
Shanghai Pituitary Tumor Center, Shanghai, China
Search for other papers by Zhaoyun Zhang in
Google Scholar
PubMed
Search for other papers by Yehong Yang in
Google Scholar
PubMed
Search for other papers by Yiming Li in
Google Scholar
PubMed
Shanghai Pituitary Tumor Center, Shanghai, China
Search for other papers by Yongfei Wang in
Google Scholar
PubMed
Search for other papers by Hongying Ye in
Google Scholar
PubMed
associated with hypercortisolism. Intensive cholesterol reduction may be beneficial in the treatment of patients with hypertension and normal lipid levels, through a reduction in large artery stiffness. Ferrier found an additional statin therapy led to a
Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Mira Jakovcevski in
Google Scholar
PubMed
.a. Waist-to-hip-ratio 67 48 1.03 1.08 n.a. n.a. n.a. n.a. n.a. Hypercholesterolemia/statin use 31 (27.0) 0 n.a. n.a. 14 (13.2) 2 n.a. n.a. 0.016 Triglycerides (mg/dL) 98 17 141.04 80.1 n.a. n
Search for other papers by Merlin C Thomas in
Google Scholar
PubMed
Search for other papers by Brendon L Neuen in
Google Scholar
PubMed
Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
Search for other papers by Stephen M Twigg in
Google Scholar
PubMed
Search for other papers by Mark E Cooper in
Google Scholar
PubMed
Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia
Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia
Search for other papers by Sunil V Badve in
Google Scholar
PubMed
-pressure-independent renoprotective actions appear modest and limited to the prevention of new-onset macroalbuminuria ( 23 ). The use of high-potency statins in patients with CKD is also standard of care ( 15 ) because the CV risk of most people with T2D and CKD usually exceeds 10
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Selina Mäkinen in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Neeta Datta in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Yen H Nguyen in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Petro Kyrylenko in
Google Scholar
PubMed
Search for other papers by Markku Laakso in
Google Scholar
PubMed
Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Heikki A Koistinen in
Google Scholar
PubMed
Introduction HMG-CoA reductase inhibitors, statins, lower cholesterol levels by inhibiting mevalonate formation, the rate-limiting step in the cholesterol biosynthesis ( 1 ). These drugs are widely used and effective in primary ( 2 , 3 ) and
Search for other papers by Chaiho Jeong in
Google Scholar
PubMed
Search for other papers by Bongseong Kim in
Google Scholar
PubMed
Search for other papers by Jinyoung Kim in
Google Scholar
PubMed
Search for other papers by Hansang Baek in
Google Scholar
PubMed
Search for other papers by Mee Kyoung Kim in
Google Scholar
PubMed
Search for other papers by Tae-Seo Sohn in
Google Scholar
PubMed
Search for other papers by Ki-Hyun Baek in
Google Scholar
PubMed
Search for other papers by Ki-Ho Song in
Google Scholar
PubMed
Search for other papers by Hyun-Shik Son in
Google Scholar
PubMed
Search for other papers by Kyungdo Han in
Google Scholar
PubMed
Search for other papers by Hyuk-Sang Kwon in
Google Scholar
PubMed
dichotomized at the lowest 25%. We defined a statin user as a person who had a prescription of a statin within 1 year of health examination. Blood samples for measurements of serum glucose, creatinine, and lipid levels were drawn after an overnight fast. Blood
Search for other papers by Kristin Godang in
Google Scholar
PubMed
Search for other papers by Karolina Lundstam in
Google Scholar
PubMed
Search for other papers by Charlotte Mollerup in
Google Scholar
PubMed
Search for other papers by Stine Lyngvi Fougner in
Google Scholar
PubMed
Search for other papers by Ylva Pernow in
Google Scholar
PubMed
Search for other papers by Jörgen Nordenström in
Google Scholar
PubMed
Search for other papers by Thord Rosén in
Google Scholar
PubMed
Search for other papers by Svante Jansson in
Google Scholar
PubMed
Search for other papers by Mikael Hellström in
Google Scholar
PubMed
Faculty of Medicine, University of Oslo, Oslo, Norway
Search for other papers by Jens Bollerslev in
Google Scholar
PubMed
Faculty of Medicine, University of Oslo, Oslo, Norway
Search for other papers by Ansgar Heck in
Google Scholar
PubMed
Search for other papers by the SIPH Study Group in
Google Scholar
PubMed
statins in study period. The decrease in the OBS group was not significant ( P = 0.079), and there was no difference between groups ( P = 0.12). Table 2 Metabolic parameters, change over time and between the two randomization groups over
Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
Search for other papers by Josephina G Kuiper in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Aline C Fenneman in
Google Scholar
PubMed
Search for other papers by Anne H van der Spek in
Google Scholar
PubMed
Search for other papers by Elena Rampanelli in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Max Nieuwdorp in
Google Scholar
PubMed
Search for other papers by Myrthe P P van Herk-Sukel in
Google Scholar
PubMed
Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
Search for other papers by Valery E P P Lemmens in
Google Scholar
PubMed
Search for other papers by Ernst J Kuipers in
Google Scholar
PubMed
Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, Netherlands
Search for other papers by Ron M C Herings in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
that potentially decrease the risk of CRC including use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, antidiabetics (both oral antidiabetics and insulin), hormone replacement therapy, and oral contraceptives. Non-users of
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark
Search for other papers by Simon Chang in
Google Scholar
PubMed
Search for other papers by Christian Fynbo Christiansen in
Google Scholar
PubMed
Search for other papers by Anders Bojesen in
Google Scholar
PubMed
Search for other papers by Svend Juul in
Google Scholar
PubMed
Search for other papers by Anna-Marie B Münster in
Google Scholar
PubMed
Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
of disease-specific medications were assessed to indirectly evaluate the incidence and timing of comorbidities, for example, insulin or oral antidiabetics as an indicator for diabetes and statins for hypercholesterolemia. Results from clinical